Aytu BioPharma (NASDAQ:AYTU – Get Free Report) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Benzinga reports.
Other equities research analysts have also recently issued research reports about the company. Weiss Ratings cut Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, October 6th. Lake Street Capital cut shares of Aytu BioPharma from a “buy” rating to a “hold” rating and set a $2.70 price objective for the company. in a research report on Tuesday. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Finally, Zacks Research downgraded shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Aytu BioPharma currently has a consensus rating of “Hold” and a consensus target price of $8.60.
Get Our Latest Analysis on Aytu BioPharma
Aytu BioPharma Stock Performance
NASDAQ:AYTU traded up $0.83 on Tuesday, hitting $2.65. The company’s stock had a trading volume of 3,241,567 shares, compared to its average volume of 67,273. The company has a current ratio of 1.13, a quick ratio of 1.00 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average of $2.01 and a two-hundred day moving average of $2.27. The firm has a market capitalization of $28.85 million, a P/E ratio of -1.60 and a beta of 0.24. Aytu BioPharma has a one year low of $1.75 and a one year high of $3.06.
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.06. Aytu BioPharma had a negative return on equity of 56.54% and a negative net margin of 24.76%. The company had revenue of $14.84 million during the quarter, compared to the consensus estimate of $13.27 million. Research analysts predict that Aytu BioPharma will post -0.16 earnings per share for the current year.
Institutional Investors Weigh In On Aytu BioPharma
Several hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC acquired a new position in shares of Aytu BioPharma in the second quarter valued at approximately $2,336,646. Stonepine Capital Management LLC bought a new position in shares of Aytu BioPharma during the second quarter worth approximately $1,962,780. AWM Investment Company Inc. bought a new position in shares of Aytu BioPharma during the second quarter worth approximately $1,332,000. BlackRock Inc. bought a new position in shares of Aytu BioPharma during the second quarter worth approximately $49,000. Finally, Crown Advisors Management Inc. acquired a new stake in Aytu BioPharma during the 2nd quarter worth approximately $430,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.
Top Aytu BioPharma Stories
These are some of the AYTU stories that stood out recently:
- Positive Sentiment: Rosemont has agreed to acquire Aytu for $2.70 per share in cash. The deal news is the primary catalyst behind the stock’s move, though completion remains subject to the transaction’s terms. Rosemont acquisition announcement
- Positive Sentiment: Fiscal 2027 first-quarter revenue was $14.84 million, above analysts’ expectations of $13.27 million. The reported loss of $0.20 per share was also narrower than the $0.26 loss estimate cited in some reports. Quarterly results and acquisition
- Negative Sentiment: Lake Street Capital downgraded AYTU from “buy” to “hold,” setting a $2.70 price target. With the target matching the cash offer price, the rating signals limited potential upside at the current level if the deal closes as announced.
Aytu BioPharma Company Profile
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
See Also
- Five stocks we like better than Aytu BioPharma
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
